ArticlePediatric blood & cancer2015

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).

Mignon L Loh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.